Mass spectrometry (MS) profiling has been investigated as a predictor for overall survival after treatment with EGFR inhibitors in non-small cell lung cancer (NSCLC), 1,2,3,4 HNSCC, 5 and ...
The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...
In a recent paper, Agulnik and co-workers have reported the results of a phase I/II trial of the EGFR-inhibitor erlotinib, given in combination with cisplatin, in patients with HNSCC. Using ...
6monon MSN
In 2017, Prof Iyer and his research team identified mutations in a rare subset of HNSCC patients that conferred sensitivity ...
Most of the currently promising compound groups belong either to the class of EGFR inhibitors (e.g., cetuximab ... locally advanced HPV/p16-negative HNSCC tumors with or without the hypoxic ...
This second BTD designation follows the initial receipt of BTD and Fast Track designation for petosemtamab for the treatment of patients with r/m HNSCC whose disease has ... the epidermal growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback